Spaulding Clinical Research

Executive Summary

Spaulding Clinical Research is a specialized Contract Research Organization (CRO) headquartered in West Bend, Wisconsin, exclusively focused on Phase I clinical trials and clinical pharmacology studies. Founded in 2008, the company has carved a niche in the highly competitive CRO market by combining a dedicated clinical pharmacology unit with proprietary technology aimed at accelerating trial timelines, reducing costs, and improving data-driven decision-making for biopharmaceutical clients. Its service offerings span traditional Phase I execution, data management, biometrics, and specialized areas such as cardiac safety, ADME studies, and bioavailability/bioequivalence (BA/BE) assessments. By concentrating on early-phase studies, Spaulding Clinical provides a streamlined, efficient pathway for sponsors to evaluate potential drug candidates, with a strong emphasis on quality and turnaround speed. The company’s focus on technology-enabled efficiency positions it well to capture demand from small and mid-sized biotechs as well as large pharma seeking flexible, high-throughput early-stage partners. In an industry where speed and reliability are paramount, Spaulding Clinical benefits from a growing pipeline of Phase I work driven by the increasing complexity of novel therapeutics (e.g., gene therapies, biologics) and the need for robust pharmacokinetic/pharmacodynamic data. The firm’s private ownership allows it to maintain a nimble, client-focused approach without the pressures of quarterly earnings scrutiny. As drug development continues to emphasize outsourcing and specialized expertise, Spaulding Clinical is poised to expand its client base and potentially scale its operations through facility upgrades or strategic partnerships. While the company faces competition from larger full-service CROs, its deep specialization in Phase I and clinical pharmacology provides a defensible competitive advantage, making it a reliable partner for sponsors seeking focused expertise and expedited study execution.

Upcoming Catalysts (preview)

• Q3 2026Expansion of Clinical Pharmacology Unit Capacity70% success
• Q2 2026Major Contract Win with Top-20 Biopharma50% success
• Q4 2026Launch of New Digital Platform for Real-Time Trial Data Analytics60% success